Tu1829 - Peripartum Exposure to Antibiotics Induces Persistent Gut Dysbiosis, Skews Host Immune System Development and Increases Risk for Inflammatory Bowel Disease in Genetically Susceptible offspring

2018 ◽  
Vol 154 (6) ◽  
pp. S-1031
Author(s):  
Jun Miyoshi ◽  
Vanessa Leone ◽  
Karen Yang ◽  
Sawako Miyoshi ◽  
Tom O. Delmont ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Bowel Disease ◽  
System Development ◽  
Host Immune System ◽  
Gut Dysbiosis ◽  
Immune System Development ◽  
Inflammatory Bowel

scholarly journals Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease

Nutrients ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 1062 ◽  
Author(s):  
Esteban Sáez-González ◽  
Beatriz Mateos ◽  
Pedro López-Muñoz ◽  
Marisa Iborra ◽  
Inés Moret ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Environmental Factors ◽  
Intestinal Microbiota ◽  
Bowel Disease ◽  
Nutritional Intervention ◽  
Host Cells ◽  
Host Immune System ◽  
Intestinal Immunity ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract; it is a heterogeneous and multifactorial disorder resulting from a complex interplay between genetic variation, intestinal microbiota, the host immune system and environmental factors such as diet, drugs, breastfeeding and smoking. The interactions between dietary nutrients and intestinal immunity are complex. There is a compelling argument for environmental factors such as diet playing a role in the cause and course of IBD, given that three important factors in the pathogenesis of IBD can be modulated and controlled by diet: intestinal microbiota, the immune system and epithelial barrier function. The aim of this review is to summarize the epidemiological findings regarding diet and to focus on the effects that nutrients exert on the intestinal mucosa–microbiota–permeability interaction. The nature of these interactions in IBD is influenced by alterations in the nutritional metabolism of the gut microbiota and host cells that can influence the outcome of nutritional intervention. A better understanding of diet–host–microbiota interactions is essential for unravelling the complex molecular basis of epigenetic, genetic and environmental interactions underlying IBD pathogenesis as well as for offering new therapeutic approaches for the treatment of IBD.

scholarly journals The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review

2021 ◽  
Vol 22 (6) ◽  
pp. 3076
Author(s):  
Laila Aldars-García ◽  
Alicia C. Marin ◽  
María Chaparro ◽  
Javier P. Gisbert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Gut Microbiota ◽  
Bowel Disease ◽  
Microbial Colonization ◽  
Host Immune System ◽  
Inflammatory Status ◽  
Vital Functions ◽  
Microbiome Profile ◽  
Inflammatory Bowel

The importance of the gut microbiota in human health is currently well established. It contributes to many vital functions such as development of the host immune system, digestion and metabolism, barrier against pathogens or brain–gut communication. Microbial colonization occurs during infancy in parallel with maturation of the host immune system; therefore, an adequate cross-talk between these processes is essential to generating tolerance to gut microbiota early in life, which is crucial to prevent allergic and immune-mediated diseases. Inflammatory bowel disease (IBD) is characterized by an exacerbated immune reaction against intestinal microbiota. Changes in abundance in the gut of certain microorganisms such as bacteria, fungi, viruses, and archaea have been associated with IBD. Microbes that are commonly found in high abundance in healthy gut microbiomes, such as F. prausnitzii or R. hominis, are reduced in IBD patients. E. coli, which is usually present in a healthy gut in very low concentrations, is increased in the gut of IBD patients. Microbial taxa influence the immune system, hence affecting the inflammatory status of the host. This review examines the IBD microbiome profile and presents IBD as a model of dysbiosis.

Natural Products: Experimental Efficient Agents for Inflammatory Bowel Disease Therapy

2020 ◽  
Vol 25 (46) ◽  
pp. 4893-4913 ◽  
Author(s):  
Fan Cao ◽  
Jie Liu ◽  
Bing-Xian Sha ◽  
Hai-Feng Pan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Natural Products ◽  
Immune System ◽  
Bowel Disease ◽  
Therapeutic Potential ◽  
Adaptive Immune System ◽  
Receptor Protein ◽  
Intestinal Epithelia ◽  
Inflammatory Bowel ◽  
The Individual

: Inflammatory bowel disease (IBD) is a chronic, elusive disorder resulting in relapsing inflammation of intestine with incompletely elucidated etiology, whose two representative forms are ulcerative colitis (UC) and Crohn’s disease (CD). Accumulating researches have revealed that the individual genetic susceptibility, environmental risk elements, intestinal microbial flora, as well as innate and adaptive immune system are implicated in the pathogenesis and development of IBD. Despite remarkable progression of IBD therapy has been achieved by chemical drugs and biological therapies such as aminosalicylates, corticosteroids, antibiotics, anti-tumor necrosis factor (TNF)-α, anti-integrin agents, etc., healing outcome still cannot be obtained, along with inevitable side effects. Consequently, a variety of researches have focused on exploring new therapies, and found that natural products (NPs) isolated from herbs or plants may serve as promising therapeutic agents for IBD through antiinflammatory, anti-oxidant, anti-fibrotic and anti-apoptotic effects, which implicates the modulation on nucleotide- binding domain (NOD) like receptor protein (NLRP) 3 inflammasome, gut microbiota, intestinal microvascular endothelial cells, intestinal epithelia, immune system, etc. In the present review, we will summarize the research development of IBD pathogenesis and current mainstream therapy, as well as the therapeutic potential and intrinsic mechanisms of NPs in IBD.

scholarly journals 398 Towards new feeding approaches for optimizing nutritional status, immunity and host-microbiota interactions in neonatal and weaned piglets

2020 ◽  
Vol 98 (Supplement_4) ◽  
pp. 181-181
Author(s):  
Martin Lessard ◽  
Mylène Blais ◽  
Guylaine Talbot ◽  
J Jacques Matte ◽  
Ann Letellier ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Intestinal Microbiota ◽  
System Development ◽  
Feed Additives ◽  
Epithelial Cell Line ◽  
Host Immune System ◽  
Gut Health ◽  
Weaned Piglets ◽  
Immune System Development

Abstract Lactation, feeding conditions, microbial interventions and piglet growth in the first few weeks of life have important impact on the intestinal microbiota establishment and immune system development of piglets. Indeed, colostrum and milk contain various bioactive components such as immune factors, antimicrobial peptides and oligosaccharides that contribute to maintain intestinal homeostasis and regulate interactions between microbiota and host immune system. Recent results revealed that low birth weight piglet (LBWP) with poor weight gain during the first two weeks of life develop different intestinal microbiota and immune response profiles compared to high BWP (HBWP) littermates. Consequently, piglets within litters may have different resilience to infections after weaning and benefit from feed additives in a specific manner. A study has been performed to evaluate the potential of bovine colostrum extract (BC) as replacement to plasma proteins for improving gut health and resilience to Salmonella infection in piglets. Results revealed that in weaned piglets fed BC, intestinal microbiota was differently modulated and bacterial dysbiosis induced by Salmonella was restored faster. Moreover, expression of genes involved in innate immunity such as β-defensin-2 and glutathione peroxidase-2 was respectively down- and up-regulated in BC fed piglets. A combination of dietary supplementation with BC, cupper and vitamins A and D has also been tested in LBWP and HBWP, and there is clear evidence that BC in combination with other feed additives promote growth and gut health in both LBWP and HBWP. The porcine intestinal epithelial cell line IPEC-J2 was used to better understand the functional properties of BC. Results indicated that BC improves wound healing, enhances barrier function and modulates the expression of several genes involved in innate immune response. Finally, as microbial intervention, the potential of fecal transplantation to modulate intestinal microbiota and immune system development of piglets is under investigation and will be discussed.

scholarly journals Dynamic Colonization of Microbes and Their Functions after Fecal Microbiota Transplantation for Inflammatory Bowel Disease

mBio ◽  
2021 ◽  
Author(s):  
Nathaniel D. Chu ◽  
Jessica W. Crothers ◽  
Le T. T. Nguyen ◽  
Sean M. Kearney ◽  
Mark B. Smith ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Bowel Disease ◽  
Healthy Donor ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Complex Mixtures ◽  
Sick Patient ◽  
Inflammatory Bowel ◽  
Living Organisms

Fecal microbiota transplantation (FMT)—transferring fecal microbes from a healthy donor to a sick patient—has shown promise for gut diseases such as inflammatory bowel disease. However, unlike pharmaceuticals, fecal transplants are complex mixtures of living organisms, which must then interact with the microbes and immune system of the recipient.

scholarly journals Microbiota-nourishing Immunity and Its Relevance for Ulcerative Colitis

2019 ◽  
Vol 25 (5) ◽  
pp. 811-815 ◽  
Author(s):  
Mariana X Byndloss ◽  
Yael Litvak ◽  
Andreas J Bäumler
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Environmental Exposure ◽  
Large Intestine ◽  
Bowel Disease ◽  
Human Diseases ◽  
Colonization Resistance ◽  
Inflammatory Bowel ◽  
New Hypothesis

An imbalance in our microbiota may contribute to many human diseases, but the mechanistic underpinnings of dysbiosis remain poorly understood. We argue that dysbiosis is secondary to a defect in microbiota-nourishing immunity, a part of our immune system that balances the microbiota to attain colonization resistance against environmental exposure to microorganisms. We discuss this new hypothesis and its implications for ulcerative colitis, an inflammatory bowel disease of the large intestine.

scholarly journals Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy

Nanomaterials ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 2460
Author(s):  
Eden Mariam Jacob ◽  
Ankita Borah ◽  
Sindhu C Pillai ◽  
D. Sakthi Kumar
Keyword(s):  
Drug Delivery ◽  
Inflammatory Bowel Disease ◽  
Immune System ◽  
Bowel Disease ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Genetic Defect ◽  
Delivery Systems ◽  
Conventional Drug ◽  
Inflammatory Bowel

The human intestine, which harbors trillions of symbiotic microorganisms, may enter into dysbiosis when exposed to a genetic defect or environmental stress. The naissance of chronic inflammation due to the battle of the immune system with the trespassing gut bacteria leads to the rise of inflammatory bowel disease (IBD). Though the genes behind the scenes and their link to the disease are still unclear, the onset of IBD occurs in young adults and has expanded from the Western world into the newly industrialized countries. Conventional drug deliveries depend on a daily heavy dosage of immune suppressants or anti-inflammatory drugs targeted for the treatment of two types of IBD, ulcerative colitis (UC) and Crohn’s disease (CD), which are often associated with systemic side effects and adverse toxicities. Advances in oral delivery through nanotechnology seek remedies to overcome the drawbacks of these conventional drug delivery systems through improved drug encapsulation and targeted delivery. In this review, we discuss the association of genetic factors, the immune system, the gut microbiome, and environmental factors like diet in the pathogenesis of IBD. We also review the various physiological concerns required for oral delivery to the gastrointestinal tract (GIT) and new strategies in nanotechnology-derived, colon-targeting drug delivery systems.

scholarly journals A murine model of pediatric inflammatory bowel disease causes microbiota-gut-brain axis deficits in adulthood

2020 ◽  
Vol 319 (3) ◽  
pp. G361-G374 ◽  
Author(s):  
Eloisa Salvo ◽  
Patricia Stokes ◽  
Ciara E. Keogh ◽  
Ingrid Brust-Mascher ◽  
Carly Hennessey ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Early Life ◽  
Low Dose ◽  
Behavioral Deficits ◽  
Colonic Inflammation ◽  
Gut Dysbiosis ◽  
Pediatric Inflammatory Bowel Disease ◽  
Adult Mice ◽  
Inflammatory Bowel

Here we describe long-lasting impacts on the microbiota-gut-brain (MGB) axis following administration of low-dose dextran sodium sulfate (DSS) to weaning mice (P21), including gut dysbiosis, colonic inflammation, and brain/behavioral deficits in adulthood (P56). Early-life DSS leads to acute colonic inflammation, similar to adult mice; however, it results in long-lasting deficits in the MGB axis in adulthood (P56), in contrast to the transient deficits seen in adult DSS. This model highlights the unique features of pediatric inflammatory bowel disease.

scholarly journals Renal involvement in paediatric inflammatory bowel disease

2019 ◽  
Author(s):  
Mohamed Mutalib
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Renal Involvement ◽  
Host Immune System ◽  
Inflammatory Disorder ◽  
Extraintestinal Manifestation ◽  
Metabolic Complications ◽  
Chronic Inflammatory Disorder ◽  
Renal Manifestation ◽  
Inflammatory Bowel

AbstractInflammatory bowel disease (IBD), which includes Crohn’s disease, ulcerative colitis and inflammatory bowel disease unclassified, is a chronic inflammatory disorder that predominantly affects the gastrointestinal (GI) tract and has a rising incidence in both children and adults. Symptoms are caused by inappropriate inflammatory response triggered by interaction between the environment, gut microbiome and host immune system in a genetically susceptible individual. Extranintestinal manifestations of IBD are common and can affect any body system outside the gut; they can precede or run parallel to GI inflammation. Renal involvement in IBD is uncommon and can be part of extraintestinal manifestation or metabolic complications of IBD. Many medications used to treat IBD can cause renal damage. Renal manifestation in children with IBD can range from asymptomatic biochemical abnormalities to variable stages of renal impairment with significant morbidity and even mortality burden.

Sign in / Sign up

Export Citation Format

Share Document